Tianyin Pharmaceutical Inactive 10-Q2010 Q3 Quarterly report

Filed: 11 May 10, 12:00am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. sophomore Avg

New words: allocated, allocation, ancial, API, Apu, arrangement, ASU, auxiliary, biopharmaceutical, bone, capture, cautioned, chemical, comment, concept, consideration, constituent, contractual, County, Director, div, dynamic, earch, Earlier, efficiency, efficiently, element, employed, evidence, evolving, excluding, experience, fixed, flagship, Forecasted, genitourinary, Ginkgo, gum, hand, health, healthcare, high, Hugan, IASB, idend, impact, indefinite, infinite, Inflation, input, intent, ITEM, joint, JV, Kangjun, landscape, led, Lidan, lieve, lihood, low, mandatory, Manufac, modified, momentum, monthly, Neisseria, NTCM, obligation, obtain, offset, ongoing, output, Park, partnered, party, patent, Phase, predominately, prohibited, proposed, publicly, published, put, Qingrejiedu, qualifying, qualitative, quantitative, reach, realizing, reiterate, reliance, Removed, residual, retrospective, roadmap, roll, separated, shortage, Shuangxin, site, skin, soft, subsequent, suspend, trial, turing, undue, update, urinary, urogenital, usage, variable, vendor, venture, Xiaoyan

Removed: announcement, attributable, born, borrowed, broadening, capacity, commercializing, complement, composed, consummated, coupled, exempt, expanding, extensive, Food, generic, improving, issue, leadership, leading, likelihood, line, manufacturer, network, planning, positive, promotional, recruit, registration, rely, seeking, segment, similar, social, solidifying, specifically, supplier, upgrade, yield

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Tianyin Pharmaceutical similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.2

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Tianyin Pharmaceutical Co., Inc. (the “Company”) on Form 10-Q for the period ending March 31, 2010, as filed with the Securities and Exchange Commission on the date hereof (the “Report’), I, James Jiayuan Tong, Chief Financial Officer & Chief Accounting Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated.

Date: May 11, 2010

/s/ James Jiayuan Tong
	James Jiayuan Tong
	Chief Financial Officer, Chief Accounting Officer,
	Chief Business and Development Officer, Director